Determining the capability of a test compound to affect solid tumor stem cells
AssigneeThe Regents of the University of Michigan
InventorsMichael F. Clarke, Scott J. Dylla, Sanjeev Satyal
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe Regents of the University of Michigan
InventorsMichael F. Clarke, Scott J. Dylla, Sanjeev Satyal
Estimating the term…
A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumor cells in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis.
A method for determining the capability of a test compound to affect the number or frequency of solid tumor stem cells of epithelial origin, the method comprising:
A method for determining the capability of a test compound to affect the number or frequency of solid tumor stem cells of epithelial origin, the method comprising:
A method for determining the capability of a test compound to affect the number or frequency of solid tumor stem cells of epithelial origin, the method comprising:
Dependencies are inferred from the claim text.